



Board Resolution n° 1 – 2013-e

Additional Funding for AMFm Transition Year 2013

Having taken note of:

- The Global Fund decision (GF/B28/DP6) to “modify the existing AMFm business line by integrating the lessons learned from the operations and resourcing of Phase 1 of the AMFm into Global Fund grant management and financial processes”.
- The Global Fund estimate of USD 114 Million that is based on past orders fulfilled and historical needs and that is required to meet AMFm Transition Year 2013 costs.
- The request of the Global Fund Secretariat for additional funding from UNITAID of USD 40 million for the AMFm Transition Year 2013.
- The response of the Global Fund Secretariat, dated 8 February 2013, to the questions raised by the UNITAID Proposal Review Committee and the UNITAID Secretariat.

Taking into consideration the PRC recommendation that:

- UNITAID should support the AMFm Transition Year 2013 by providing up to USD 20 million with disbursement conditions that are linked with contributions and pledges from other donors and the demonstration of need for funds by the Global Fund during the AMFm Transition Year 2013.
- Funding should be based on actual/historical demands rather than estimates.

The Executive Board of UNITAID authorizes, subject to the availability of funds, the Executive Director of UNITAID to commit up to USD 20 million to support the AMFm Transition Year 2013 (Transition Funding). In addition, such Transition Funding will include the remaining unexpended balance due to UNITAID (estimated at USD 11 million) in relation the UNITAID-funded Global Fund Round 6, Phase 1 Initiative.

Transition Funding for the AMFm Transition Year 2013 will be provided by UNITAID on the condition that the Global Fund agrees to:

1. Maintain stringent screening and approval processes of artemisinin combination therapy (ACT) orders from the private-sector first-line buyer orders in beneficiary countries;
2. Inform and encourage beneficiary countries to ensure the use of AMFm co-paid ACTs in areas where they are most needed and in conjunction with diagnostic tests wherever possible; and
3. Inform and encourage countries to ensure that the price paid for AMFm co-paid ACTs by patients is as low as possible.

Philippe Douste-Blazy
Chair of the UNITAID Executive Board